UNITY Biotechnology Inc at Cowen Health Care Conference Transcript
Awesome, well, thank you, Anirvan from Unity for being here at the 43rd Annual Cowen Healthcare Conference. So excited to have you here [because we're excited about your story. So thank you for joining us virtually. So I will turn it to you, Anirvan].
Right. Thanks. I'm pleased to provide an update on our lead program, UBX1325 and our upcoming data readouts in the coming months. Before I get started, I just wanted to remind you that I'll be making forward-looking statements during my presentation today that are summarized over here and detailed in our SEC filings.
At Unity, we are developing a new class of therapeutics called senolytics to target progressive vision loss. The two indications are primarily focused on our diabetic macular edema and age-related macular degeneration. These are two major causes of vision loss globally. And despite being one of the standard of care treatment anti-VEGF, many patients do not get to 2040 or otherwise good vision.
We recently shared Phase 2 data
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |